Trials / Completed
CompletedNCT00092391
A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,997 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 12 Months – 18 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live | 0.5 mL subcutaneous injection of one of three sub-lots on Day 0 |
| BIOLOGICAL | Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck) | 0.5 mL subcutaneous injection on Day 0 |
Timeline
- Start date
- 1999-02-01
- Primary completion
- 2001-07-01
- Completion
- 2001-07-01
- First posted
- 2004-09-27
- Last updated
- 2015-10-23
Source: ClinicalTrials.gov record NCT00092391. Inclusion in this directory is not an endorsement.